WO2025238663 - SAROGLITAZAR FOR THE TREATMENT OF ALCOHOLIC LIVER DISEASES
National phase entry is expected:
Publication Number
WO/2025/238663
Publication Date
20.11.2025
International Application No.
PCT/IN2025/050762
International Filing Date
16.05.2025
Title **
[English]
SAROGLITAZAR FOR THE TREATMENT OF ALCOHOLIC LIVER DISEASES
[French]
SAROGLITAZAR POUR LE TRAITEMENT DE MALADIES HÉPATIQUES ALCOOLIQUES
Applicants **
ZYDUS LIFESCIENCES LIMITED
Inventors
ZAWARE, Pandurang
GIRI, Suresh
JAIN, Mukul
BHOI, Bibhuti Bhusan
PINGALI, Harikishore
Priority Data
202421038434
16.05.2024
IN
Application details
| Total Number of Claims/PCT | * |
| Number of Independent Claims | * |
| Number of Priorities | * |
| Number of Multi-Dependent Claims | * |
| Number of Drawings | * |
| Pages for Publication | * |
| Number of Pages with Drawings | * |
| Pages of Specification | * |
| * | |
| Number of Office Actions | * |
| * | |
International Searching Authority |
IP India
* |
| Recordal of a Change of the Applicant's Name/Address |
Change of Applicant's Name and Address
* |
| Type of Assignment |
The Standard Agent's Assignment
* |
| Applicant's Legal Status |
Legal Entity
* |
| * | |
| * | |
| * | |
| * | |
| * | |
| Entry into National Phase under |
Chapter I
* |
| Patent Delivery |
Send the Letters Patent by Courier
* |
| Translation |
|
* The data is based on automatic recognition. Please verify and amend if necessary.
** IP-Coster compiles data from publicly available sources. If this data includes your personal information, you can contact us to request its removal.
Quotation for National Phase entry
| Country | Stages | Total | |
|---|---|---|---|
| China | Filing, Examination, Granting | 2426 | |
| EPO | Filing, Examination, Granting | 17170 | |
| Japan | Filing, Examination, Granting | 2492 | |
| South Korea | Filing, Examination, Granting | 2868 | |
| USA | Filing, Examination, Granting | 6540 |
Total:
31,496
Contact Us
Abstract[English]
The present invention provides low dose of Saroglitazar of Formula (I) or its pharmaceutically acceptable salts for the prevention and treatment of Alcoholic liver diseases. Further, the present invention provides low dose of Saroglitazar of Formula (I) or its pharmaceutically acceptable salts for the prevention and treatment of Alcoholic liver diseases.[French]
La présente invention concerne une faible dose de saroglitazar de formule (I) ou ses sels pharmaceutiquement acceptables pour la prévention et le traitement de maladies hépatiques alcooliques. En outre, la présente invention concerne une faible dose de saroglitazar de formule (I) ou ses sels pharmaceutiquement acceptables pour la prévention et le traitement de maladies hépatiques alcooliques.